Table 2. Baseline characteristics of newly diagnosed people with HIV according to anti-retroviral resistance results during 2012 - 2020.
| Characteristics | Resistance (n = 30) | No resistance (n = 218) | P | |
|---|---|---|---|---|
| Age (median, IQR) | 28 (23 - 44) | 31 (26 - 44) | 0.279 | |
| Male, n (%) | 28 (93.3) | 206 (94.5) | 0.524 | |
| Comorbidity, n (%) | 5 (16.7) | 30 (13.8) | 0.421 | |
| Diabetes mellitus | 2 (6.7) | 6 (2.8) | 0.250 | |
| Hypertension | 0 (0.0) | 12 (5.5) | 0.205 | |
| CVD | 0 (0.0) | 3 (1.4) | 0.678 | |
| Chronic hepatitis B | 1 (3.3) | 7 (3.2) | 0.649 | |
| Chronic hepatitis C | 0 (0.0) | 4 (1.8) | 0.595 | |
| Liver cirrhosis | 0 (0.0) | 1 (0.5) | 0.879 | |
| Solid organ tumor | 0 (0.0) | 3 (1.4) | 0.678 | |
| Lymphoma | 2 (6.7) | 1 (0.5) | 0.039 | |
| Previous ART history, n (%) | 0 (0.0) | 6 (2.8) | 0.457 | |
| Laboratory results (median, IQR) | ||||
| White blood cell count, /mm3 | 4,530 (3,363 - 6,078) | 5,170 (4,138 - 6,415) | 0.138 | |
| CD4+ T cell count, /mm3 | 233 (47 - 402) | 256 (116 - 399) | 0.856 | |
| HIV RNA, copies/mL | 60,320 (15,441 - 408,928) | 48,815 (13,280 - 152,005) | 0.218 | |
| AST, IU/L | 27 (22 - 41) | 25 (21 - 33) | 0.604 | |
| ALT, IU/L | 29 (15 - 46) | 23 (17 - 34) | 0.173 | |
| Albumin, g/dL | 4.2 (3.9 - 4.5) | 4.3 (3.8 - 4.5) | 0.776 | |
| Creatinine mg/dL | 0.80 (0.70 - 0.86) | 0.79 (0.72 - 0.88) | 0.598 | |
Values are counts (%) or median (interquartile range) as indicated.
HIV, human immunodeficiency virus; IQR, interquartile range; CVD, cardiovascular diseases; AST, aspartate aminotransferase; ALT, alanine aminotransferase.